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Thermography: is a new diagnostic method necessary
for breast cancer detection?
Human history becomes a race between knowledge and catastrophe
Despite everything, the world progresses and will progress
Herbert George Wells
Breast cancer is the most common cancer in women worldwide (in2010, nearly 1.5 million people were told: »You have breast can-
cer«). It is also the principal cause of 500,000 deaths from cancer among
women globally (1). The progress achieved in diagnosis and treatment
of breast diseases offers encouragement to both physicians and diseased
women; the physicians have managed to save many lives, and many
lives have been prolonged.
The World Health Organization (WHO) has proposed that two
components of early detection have been shown to improve cancer
mortality rate (1): education – helps people recognize early signs of
cancer and seek prompt medical attention for symptoms and screening
programs – identify early cancer or pre-cancer condition before signs
are recognizable, including breast cancer mammography.
Medical community – and particularly its segment that deals with
this problem area – is almost daily exposed to: new guidelines for appli-
cation of diagnostic and screening protocols (2, 3, 4, 5).
Also, the participation of new genes as predictors of disease progno-
sis and outcome has been revealed (6), the need for new standardiza-
tion of current immunohistochemistry protocols has been emphasized
(7), new pharmaceutical preparations have been included for the breast
cancer treatment that are at various stages of clinical trials (8, 9), some
drugs are excluded from standard protocols (10) and warnings are is-
sued on the hazards accompanying introduction of new diagnostic
methods in clinical practice (11).
Undoubtedly, we are now at a stage when, with a multitude of rec-
ommendations, protocols, cautions and new preparations, it is increas-
ingly hard for physicians – and particularly for patients – to decide for
optimal solution. Clearly, the present state requires re-examination of
existing values, which at the same time poses new challenges, doubts
and responsibilities for medical staff.
All the references cited above were published in 2011. except for the
article (11) that was published in 2010.
The most important points that have been stated in the foregoing





Received December 2, 2011.
PERIODICUM BIOLOGORUM UDC 57:61
VOL. 113, No 4, 393–399, 2011 CODEN PDBIAD
ISSN 0031-5362
Essay
1. The authors observed that American Cancer Society
guidelines established in 2007 are not valid any more.
Despite the higher sensitivity of MRI, it is uncertain
whether MRI screening has provided a survival ad-
vantage. »In patients with breast cancer, there is little
evidence that MRI improves short-term or long-term
outcomes of breast-conserving surgery«, the resear-
chers stated. Ultimately, the true value of MRI might
lie in its ability to predict biological behavior, rather
than to quantitate low-volume disease. Future re-
search in this field would be most beneficial if di-
rected toward the resolution of clinical problems such
as assessment of the extent of residual disease after
neoadjuvant chemotherapy or of the need for some
form of radiation therapy in all women who undergo
breast-conserving surgery (2).
2. The American College of Radiology Imaging Net-
work (ACRIN 6666) protocol – a study to define the
rationale for screening breast ultrasound – protocol
investigators found that interpretive errors were re-
sponsible for 28% (19 of 67) of cancers missed on
mammography, 21% (15 of 71) of cancers missed on
ultrasound, and 20% (1 of 5) missed on MRI (3). The
results point to the need to improve interpretive skills,
but whether this is possible is unclear, said the princi-
pal investigator Wendie A.Berg. »These investigators
had all gone through multiple qualification tasks and
were all physicians. You would expect them to be
about as good as they can be, yet about 20% of cancers
that were visible and documented on both mammog-
raphy and ultrasound were misinterpreted.« The in-
vestigators believe automated scanning and compu-
ter-assisted detection and diagnosis would improve
breast cancer detection rates.
3 The reduction in mortality associated with screening
mammography is relatively small for women aged
40–74 years at average risk of breast cancer (4).
4. A greater reduction in mortality is seen with mam-
mography for women at average risk aged 50–74 years
than among similar women aged 40–49 years; how-
ever, harms of over-diagnosis and unnecessary biopsy
may be greater for younger women than for older
women (4).
5. When deciding whether to recommend mammogra-
phy to a specific patient, providers should first discuss
the tradeoff between benefits and harms, as well as
the patient’s values and preferences (4).
6. For women at average risk who choose to have scre-
ening mammography, an interval of every two to
three years appears appropriate (4).
7. There is no evidence that screening women at aver-
age risk of breast cancer using magnetic resonance
imaging, clinical breast examination or breast self-ex-
amination reduces the risk of mortality or other clini-
cally relevant adverse outcomes (4).
8. MRI detects cancer not identified with other types of
screening. In two randomized trials, this increased
sensitivity did not translate into improved selection of
surgical treatment or a reduction in the number of
operations (5).
9. Gene expression profiling studies have shown that es-
trogen-receptor (ER)-positive and ER-negative breast
cancers are distinct diseases at the transcriptomic le-
vel, that additional molecular subtypes might exist
within these groups, and that the prognosis of pa-
tients with ER-positive disease is largely determined
by the expression of proliferation-related genes (6).
10. The 21-gene assay, when applied in a consistent man-
ner at an early stage of breast cancer, changes treat-
ment recommendations in one quarter of patients
tested (6).
11. The assessment of HER2 status in breast cancer is
critical for the management of disease and therefore a
priority for pathological standardization. The selec-
tion of the most appropriate adjuvant treatment regi-
men, including whether a patient is a candidate for
HER2-targeted therapy, is heavily dependent on reli-
able and accurate laboratory results assessing the HER2
status as part of their diagnostic evaluation (7).
12. Everolimus (EVE), an inhibitor of the PI3K/Akt/
mTOR pathway, has single-agent activity and pro-
vides additional efficacy to long-term estrogen depri-
vation when combined with letrozole in the neoadju-
vant setting. Combination of EVE and exemestane
may improve outcomes for patients ER+ breast can-
cer refractory to nonsteroidal aromatase inhibitors
(NSAI) (8).
13. Roche’s investigational medicine T-DM1 shows im-
provement in progression-free survival compared to
the standard of care in HER2-positive metastatic bre-
ast cancer. First randomized trial of an antibody drug
conjugate (ADC) for metastatic breast cancer has
highlighted importance of personalized approach to
cancer care (9).
14. Avastin used for metastatic breast cancer has not been
shown to provide a benefit, in terms of delay in the
growth of tumors, that would justify its serious and
potentially life-threatening risks. Nor is there evi-
dence that use of Avastin will either help women with
breast cancer to live longer or improve their quality of
life (10).
15. The new methods are breast-specific gamma imaging
(BSGI) and positron emission mammography (PEM),
both of which have been recently approved for use in
the United States. They are marketed as diagnostic
adjuncts to mammography and breast ultrasound,
but they can also be considered for breast cancer
screening, particularly in women at an increased risk
for breast cancer, he adds. However, the radiation in-
volved in a single BSGI examination poses a risk that
is 20 to 30 times greater than that from digital mam-
mography in a woman 40 years of age, and the risk
from a single PEM screen is 23 times higher (11).
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»Modern science has entered a stage when »facts are uncer-




We live in a world characterized by critical rationalism
where scientific insight has become a paradigm for inter-
preting life and the world, and a signpost for quality liv-
ing. Nevertheless, changes have never been occurring so
quickly as in our time nor did the criticality have such a
freedom of influence. This is particularly evident in the
area of knowledge related to new inventions.
According to Herman et al. (12), the biological initia-
tion of breast cancer occurs as early as 9 years before it
could be observed mammographically while, according
to the Collins’ law (13), the time from the biological on-
set of breast cancer until the moment of its diagnosis has
been estimated to be 5–6 years. According to Herman, as
many as 15 years may pass from the biological onset of
the disease until the appearance of clinical manifesta-
tions of the breast cancer. A woman has, on average,
three years of life since the appearance of clinical symp-
toms of the breast cancer. Preclinical and clinical stages
could be distinguished in the progression of disease.
Three crucial elements are prominent in the preclinical
stage of disease: biological onset of disease, the disease
that can be verified by a screening test, the critical point,
and the beginning of treatment. The clinical stage of dis-
ease begins with the appearance of symptoms. It is indis-
putable that the optimal beginning of treatment should
occur at the moment of diagnosing disease at the preclin-
ical stage, since otherwise no effect is achieved. On the
other hand, the effect of screening may be questionable if
a detected change is too slight, is at the lower limit of de-
tection, and perhaps represents a pseudodisease. Pseu-
dodisease is a condition that does not require treatment
since it does not affect the duration or quality of a sub-
ject’s life.
In this regard, a question may be posed if mammogra-
phy is satisfactory as a recent method of choice, or a more
effective procedure could be applied (12).
So far, four sets of problems related to diagnosis and
treatment of breast cancer have been formulated, consid-
ered and developed, and are open for discussion. Those
are as follows:
1. Revision of current diagnostic and screening pro-
tocols
The survival of individuals with the diagnosed breast
cancer depends on the size of tumor, its biological char-
acteristics, expansion of disease, and patient’s age.
Mammography is currently the elementary diagnostic
test for breast cancer detection, and is the basis of all
screening programs worldwide. Satisfaction and enthu-
siasm that lasted for over 30 years has today, mildly
speaking, been replaced by scepticism (14, 15). The sen-
sitivity of mammography depends significantly on the
density of breast parenchyma and declines in proportion
to this density, amounting to 48% for very dense breasts,
which makes it a very unreliable method for cancer de-
tection in young women (under 50 years of age) (16).
Based on the data reported in the Journal of the Americal
Medical Association in 2008 from the American College
of Radiology Imaging Network (ACRIN 6666), more
than half of the women under 50 years of age have dense
breasts, as well as 30% of women older than 50 years in
whom the sensitivity of mammography ranges from 38%
to 48% and is accompanied with higher cancer frequ-
ency, more frequent incidence of interval cancers, and
poorer prognosis. The authors point out that the inclu-
sion of ultrasound examination in a standard clinical
protocol raises the sensitivity to 77.5%, and therefore
support this inclusion. However, despite the fact that the
number of affected women is high and has a rising ten-
dency among younger age groups, each new solution
should without exception undergo reexamination (15,
17) concluded in their study that none of the diagnostic
or screening methods does by itself fulfill the expecta-
tions of the present time.
2. Detection of the biological properties of the breast
tumor that indicate the need for individual therapy
Breast cancer is a complex genetic disease character-
ized by accumulation of altered molecules that cause the
clinical heterogeneity of the disease, and that affect not
only the treatment but also its prognosis. These mole-
cules are presently used as prognostic factors (the status
of lymph nodes, tumor size, histological grade, hormone
receptor status, protein HER2/human epidermal growth
factor/patient’s expression and age), yet they have shown
to be insufficiently accurate predictors of the clinical
course and outcome of the disease for about 30% of pa-
tients (18).
According to molecular classification of the breast tu-
mor, there are several molecular subtypes that are de-
pendent on the presence or absence of steroid receptors
(estrogen and progesterone), i.e. on the presence or ab-
sence of reaction to the presence of HER2 protein (hu-
man epidermal growth factor) (19).
In addition to the above mentioned predictors, the de-
termination of tumor cell proliferation has been intro-
duced into the clinical practice as one of the most signifi-
cant prognostic factors for tumors in general.
Depending on the foregoing predictors, the treatment
of the breast cancer is based on the following: neoadju-
vant chemotherapy, surgical treatment, adjuvant chemo-
therapy and hormone therapy and radiation.
3. Detection of those biological properties of the carci-
noma in situ that point to its potential for transition
to invasive cancer
The term carcinoma in situ is used to define tumors in
which the proliferation of malignant epithelial cells takes
place within the boundaries of the basal membrane. The
concept of the carcinoma in situ as a predictor of invasive
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cancer has remained active to serve like a bridge that cov-
ers the gap between benign epithelial proliferation and
invasive cancer. In approximately 50% of patients, inva-
sive cancer progresses from carcinoma in situ, which
means that approximately 50% of patients are treated
more invasively than required by the nature of the dis-
ease itself.
The diagnosis of DCIS »is a 30-year history of confu-
sion, differences of opinion and under- and overtreat-
ment«, said Shahla Masood, MD, the head of pathology
at the University of Florida College of Medicine in Jack-
sonville, in the New York Times article (20).
What are the most critical research questions for the
diagnosis and management of DCIS?
The diagnosis and management of DCIS is highly
complex with many unanswered questions, including
the fundamental natural history of untreated disease.
Because of the noninvasive nature of DCIS, coupled
with its favorable prognosis, strong consideration should
be given to remove the anxiety-producing term »carci-
noma« from the description of DCIS. The outcomes in
women treated with available therapies are excellent.
Thus, the primary question for future research must fo-
cus on the accurate identification of patient subsets diag-
nosed with DCIS, including those persons who may be
managed with less therapeutic intervention without sac-
rificing the excellent outcomes presently achieved. Es-
sential in this quest will be the development and valida-
tion of accurate risk stratification methods based on a
comprehensive understanding of the clinical, radiologi-
cal, pathological, and biological factors associated with
DCIS (21).
According to the latest studies by Kerlikowska et al.
(22), two basic characteristics of the ductal cancer in situ
were found that make it a cancer precursor:
1. size
2. pronounced presence of biological markers (p16,
cyclooxygenase (COX)-2 and Ki67).
4. Biological properties of benign diseases that are breast
cancer precursors
A broad range of changes in the breast, »typical« be-
nign on one hand and »typical« malignant changes in the
breast on the other, fills up a still unclearly defined space
that comprises changes with some (undefined) role in
the transition from one of these states into another. Be-
nign atypical hyperplasia (BAH) does not represent a di-
rect precursor of the breast cancer but is rather an indica-
tor of increased risk for its occurrence. Some studies have
demonstrated the existence of strong correlation between
the amount of estrogen found in biopsied lesions and
subsequent occurrence of cancer (23). Also, the absence
of expression on CK5 (cytokeratin 5) in atypical ductal
hyperplasia is considered a malignant disease, i.e. ductal
carcinoma in situ (24).
WHAT IS THERMOGRAPHY?
Thermography is a biologically inert, contactless di-
agnostic method based on the recording of the heat
emitted from the human body using a sensitive infrared
camera.
FDA (Food and Drug Administration, 1982) appro-
ved the thermography procedure as a method for early
breast cancer detection. Mammographic and ultrasound
examinations are based on the physical change in dis-
eased tissue, similarly to all other diagnostic methods ex-
cept thermography. Apart from recording physical chan-
ges in the structure of diseased tissue, the sensitivity of
the magnetic resonance method is also based on the abil-
ity to detect newly formed blood vessels in tumor forma-
tions, i.e. angiogenesis.
Angiogenesis has important role also in the local breast
tumor growth and in formation of distant metastases.
Metabolic activity and vascular network in precancerous
formations and in the surroundings of a growing breast
tumor are always more pronounced than in the normal
breast tissue. The concept of angiogenesis as an initial
event in the breast cancer formation was demonstrated in
1996 (25). The observation of these authors confirmed
that angiogenesis and increased metabolic activity begin
before the carcinoma in situ has been microscopically
registered. Cancerous breast hyperthermia is seemingly
associated with non – neurological vasodilatation modu-
lated by nitric oxide (26). The roles of nitric oxide (NO)
in numerous disease states have generated considerable
discussion over the past several years. NO can also have a
multitude of effects on other aspects of tumor biology, in-
cluding angiogenesis and metastasis and may impact the
initiation and progression stages of cancer (27). The
thermographic visualization of »blood vessels« in ther-
mograms is a consequence of need for abundant supply
of nutritiens to maintain of the tumor growth. In order to
do this, they increase circulation to their cells by sending
out NO (nitric oxide) to keep existing blood vessels open,
recruit dormant vessels and create new ones (neoangio-
genesis).
The basic principle of thermography is detection of
increased temperature that is produced by enhanced me-
tabolic activity of a proliferating tumor. The process of
carcinogenesis is associated with the process of angio-
genesis, which leads to increased temperature of the skin
above the growing tumor.
Usual skin temperature increase on the surface of the
breast with a growing tumor is 1–3 °C. In studies (26, 28,
29, 30, 31) in which the nature of temperature disorders
was investigated on the skin of a subject under observa-
tion, these disorders are explained with several biological
principles, or by the effect of different factors on patho-
logical events characterized by the dynamics of tempera-
ture fluctuations:
1. Nitric oxide (NO) is a vasodilatory substance that is
normally found in the body. It is produced by white
blood cells during activation of the immune system,
but is also produced by tumor cells. As a vasodilatory
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substance, NO provides the tumor with nutritive sub-
stances and gives rise to temperature increase in the
environment. Vasodilation that occurs in tumor envi-
ronment is not under the control of central neurologi-
cal, sympathetic and parasympathetic impulses. The
quantity of NO synthetase found in breast tumors
shows some correlations with biological activity of the
tumor and its expression of estrogen.
2. Increased amount of ferritin in tumor cells is also as-
sociated with the production of nitric oxide (NO) as a
source of Fe²+ that serves as a catalyst in the process
of its formation.
3. Angiogenesis is a process that follows tumor growth.
The tumor growth is accompanied with an increased
need for nutrients and oxygen which is ensured by
formation of additional blood vessels. In this patho-
logical and chaotic process of angiogenesis, the newly
formed blood vessels lack a layer of smooth muscle
cells in the vessel wall, which makes normal vasocon-
triction in these pathological vessels impossible and
thus contributes to increased thermal activity.
4. Inflammation is another factor that causes tempera-
ture rise in tumor environment. As in the case of
wound infection, tumor itself produces inflammation
moderators and furnishes additional necessary nutri-
ents.
5. Estrogen is a hormone found in circulation and is one
of the mediators of vasodilation that leads to increased
local production of nitric oxide (NO) so that abnor-
mal amounts of estrogen may lead to vasodilation in
estrogen-sensitive tissues and thus increase environ-
mental temperature.
WHAT IS THE SIGNIFICANCE OF
THERMOGRAPHY INTRODUCTION
INTO ROUTINE CLINICAL PRACTICE?
The application of thermography in breast cancer di-
agnostics marks the shift from morphological to biologi-
cal onset of disease, Figure 1.
How does the possibility of introducing biological
properties of disease affect the routine clinical practice?
It questions everything: privileges, habits, inertness.
The method of thermography, as a very sensitive bio-
logical method, provides a physician with guidelines for
the necessary further diagnostic and therapeutic proce-
dures, yet it requires from the physician to become ac-
quainted with the biological bases of breast disease as a
prerequisite for the method application.
Initial experiences in thermography application in
Croatia (on experimental model) were registered by Po-
ljak – Bla`i M. et al. (32) in 2009. First clinical trials that
included thermography as a diagnostic method in breast
disease diagnostics were registered in the master’s thesis
by Herceg (33) entitled: »Evaluation of benign and ma-
lignant signs of breast pathology on mammography and
thermography«.
In 2011, the Croatian Ministry of Science, Education
and Sports accepted to co-finance: a project »Thermo-
graphy – a Method of Early Breast Cancer Detection«
(BICRO Poc3_03_35). The study was carried out with
the aim to compare mammographic and thermographic
methods as clinical and screening methods. Preliminary
results of the project are as follows: none of the female
subjects with clinically confirmed breast disease had neg-
ative thermographic finding, i.e. a finding where patho-
logical thermographic signs could not be observed and
upon including thermography in the screening program,
five more cases of cancer were detected in a sample of 100
women as compared to mammography alone.As result of
the study, a new method of simplified description and in-
terpretation of pathological thermography signs in malig-
nant breast lesions was developed on the basis of existing
protocols (Marseille, Villa – Maria, Hobins, Hoekstra)
(17, 34).
The effect of this new and simplified standardization
of interpretation in thermographic method will be easier
acceptance of the method by a broad circle of users (diag-
nosing physicians, surgeons, oncologists, medical radiol-
ogy engineers and, which is most important, by women).
Past experience worldwide with the application of this
method may be divided into two periods: a period of
thermography application in the framework of currently
surpassed technical solutions and a period when all tech-
nical and technological advancements have enabled sim-
ple application of thermography.
Our results could be compared only to the results
from the second period above when cameras of the same
generation and resolution have been used.
Results and experiences of various authors with the
use of thermographic technology in the diagnosis of bre-
ast cancer are very hard to compare, both among them
others and with our results (17, 35, 36, 37, 38, 39, 40) for a
number of reasons: initial objectives of those studies were
completely different, attempts were made in some stud-
ies at computerized automated sample recognition, ther-
mography was partly compared with other diagnostic
methods, the same standards were not used in reports,
there were great differences in the number of examined
female subjects, etc.
However, we could point out possible comparison
with only two studies where sensitivity and specificity of
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Figure 1. The diagram shows several time points related to disease ap-
pearance and progression: the time of the biological onset of disease
and morphological changes which could be seen on mammography,
and the time from the clinical manifestation of disease (modified ac-
cording to Herman) (12).
the thermography method was estimated in female sub-
jects examined immediately prior to biopsy or breast sur-
gery, i.e. the studies by Parisky (35) and by Kontos (39).
On a sample of 875 changes determined by biopsy,
Parisky pointed out the high sensitivity of the method
(97%) and the specificity of 14%. Unlike him, Kontos re-
ported low method sensitivity (25%) and significantly
high specificity (85%) in a study that included samples
from 63 subjects (male subjects with breast cancer were
also included in the study). Regarding such markedly
contrary results, it is difficult to put forward any value
judgement at all both on the method itself and the man-
ner of result interpretation. According to our experience
based on (33), the sensitivity of the method was 100%
while specificity was somewhat lower (74%) since we re-
garded as a positive result of thermographic examination
every recorded change in the breast (atypia, fibroadeno-
mas, phyllodes tumors, invasive cancers, and carcinoma
in situ).
Thermography – as a method with high potential for
detection of breast tissue changes – is a valuable diagnos-
tic method that should be standardized by implementa-
tion of multicentered studies and establishment of iden-
tical objectives.
CONCLUSION
Thermography – as a method with high potential for
detection of breast tissue changes – is a valuable diagnos-
tic method that should be standardized by implementa-
tion of multicentered studies and establishment of iden-
tical objectives.
Early detection of breast cancer poses a demanding
situation for all physicians, from those engaged in diag-
nostics to those who deal with therapeutic procedures.
Taking into account that new biological and clinical in-
dicators of disease are detected almost daily, we may live
in a time that is reminiscent of the time of great geo-
graphical discoveries five centuries ago. Unlike then, at
the present moment I have a feeling that we lack persons
who would delineate each particular finding into a large
geographical map.
Employment of a new diagnostic method that shows
promise of pointing to the biological onset of disease pri-
marily requires the renouncement of acquired habits
and of the pleasure of applying already learnt methods; it
also entails additional efforts by already burdened and
»confused« physicians. Still, the attempt to attain the
ideal of »curability« of the breast cancer as the deadliest
cancer that affects women should be an additional mo-
tive to all who are engaged in this problem area. The
search for new technologies and techniques for early dis-
covery breast changes, while still in curable stage, repre-
sents »conditio sine qua non« of future advancement in
this area.
A possibility that thermography findings are stan-
dardized, that computerized neural network systems are
improved, that the findings are assessed by interdisci-
plinary expert teams, that biologists may also become
included in decision-making about the beginning of
treatment should be sufficient to ensure an enthusiastic
start of the wide application of this method, with the
hope that it will in a reasonably short period contribute to
reduction in breast cancer mortality.
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